Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024 ...

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune ...

Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which ...

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

As it advances its nonopioid analgesic ATX-101 breakthrough therapy through a phase IIb registration trial, Allay Therapeutics secured $57.5 million in a series D round, which included an investment ...

A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on ...

Researchers at ETH Zürich developed Menstruai, a device that detects in menstruation blood biomarkers associated with certain ...

Human adenovirus may cause severe infections in both immunosuppressed and immunocompetent individuals and there is no ...

Rakuten Medical Inc.’s RM-0256 has been selected for funding by Japan’s Agency for Medical Research and Development (AMED).

The EMA has issued a new guideline on how to include and/or retain pregnant and breastfeeding women in clinical trials, in a ...

In yet another China antibody-drug conjugate (ADC) deal, Astellas Pharma Inc. is inlicensing a phase I/II ADC targeting Claudin 18.2 from Evopoint Biosciences Co. Ltd. for up to $1.34 billion.